Get the Stockscreener App
0.8625
0.52%
-0.0045
After Hours:
.90
0.0375
+4.35%
Context Therapeutics Inc stock is traded at $0.8625, with a volume of 77,184.
It is down -0.52% in the last 24 hours and up +56.51% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.867
Open:
$0.87
24h Volume:
77,184
Relative Volume:
0.48
Market Cap:
$89.70M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.9478
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-13.75%
1M Performance:
+56.51%
6M Performance:
-62.00%
1Y Performance:
-36.58%
1-Day Range:
$0.8201
$0.8905
1-Week Range:
$0.80
$0.9964
52-Week Range:
$0.55
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.8625 | 89.70M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.86 | 126.60B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.00 | 64.75B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
639.90 | 36.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.13 | 31.40B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
102.43 | 28.98B | 2.98B | -717.57M | -264.74M | -2.9987 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World
Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India
Context Therapeutics Presents Preclinical and Translational - GlobeNewswire
Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan
Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - Nasdaq
Bet on These 5 Top-Ranked Stocks With Rising P/E - NewsBreak: Local News & Alerts
William Blair starts Context Therapeutics stock with Outperform By Investing.com - Investing.com Canada
Stocks in play: Parkland Corporation - The Globe and Mail
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - ADVFN
Context Therapeutics Reports Full Year 2024 Operating and Financial Results - ADVFN
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
D. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
Context Swoons on CT-95 First Dose - Baystreet.ca
Context Therapeutics Begins Phase 1 Trial for CT-95 - TipRanks
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - GlobeNewswire
Breakthrough Cancer Treatment Launches Trial: Targets 30% of All Cancer Types - Stock Titan
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Yahoo Finance
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Yahoo Finance
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo
Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Context Therapeutics Unveils Packed Schedule: 4 Elite Healthcare Conferences Coming Up - Stock Titan
Context Therapeutics: 2024 Financial and Strategic Highlights - TipRanks
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Brokerages - Defense World
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView
Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 - Stock Titan
JMP maintains $4 target on Context Therapeutics stock By Investing.com - Investing.com UK
What is HC Wainwright’s Forecast for CNTX Q3 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Yahoo Finance
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN
Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Inc. (CNTX) reports earnings - Quartz
Context Therapeutics Secures 3-Year Cash Runway with $94M War Chest, Expands Cancer Pipeline - StockTitan
Context Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025 - Nasdaq
Context Therapeutics Inc. SEC 10-K Report - TradingView
CONTEXT THERAPEUTICS Earnings Preview: Recent $CNTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure - Business Wire
Context Therapeutics (CNTX) to Release Earnings on Thursday - Defense World
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors - StreetInsider.com
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):